Point72 Asset Management
ADMA icon

Point72 Asset Management’s ADMA Biologics ADMA Stock Holding History

Point72 Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294K Buy
+35,100
New +$320K ﹤0.01% 3389

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Point72 Asset Management's ADMA Position: Q2 2026 in Review

Point72 Asset Management reduced its ADMA Biologics (ADMA) stake by 87% in Q2 2026, selling an estimated $26.2M and leaving 413,935 shares worth $3.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2028.

Point72 Asset Management first reported a position in ADMA in Q1 2020 and has held it in 12 quarters since. The position peaked at $29.6M in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Point72 Asset Management held 413,935 shares of ADMA Biologics worth $3.46M as of Q2 2026.
  • Point72 Asset Management sold 2,874,822 ADMA Biologics shares in Q2 2026, an estimated $26.2M.
  • ADMA Biologics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #2028 holding.
  • Point72 Asset Management first reported a position in ADMA Biologics in Q1 2020 and has held it in 12 quarters since.
  • Point72 Asset Management's ADMA Biologics position peaked at $29.6M in Q1 2026.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.